Scholarlink

<p>CAR-NK cells offer a promising immunotherapy approach, addressing key CAR-T cell limitations like reduced toxicity risks while retaining targeted efficacy. They combine the innate cytotoxicity of natural killer (NK) cells with the targeted action of chimeric antigen receptors (CAR). Their potential lies in efficacy, tolerability and the possibility of off-the-shelf production, enabling rapid treatment access. However, CAR-NK cells are still in early development with ongoing clinical trials. The next years will determine their potential for clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CAR-NK-Zellen: die nächste Innovation der Krebsimmuntherapie?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月8日

查看全文
  • Katharina Schindler-Wnek,
  • Dominik Schmiedel

摘要

CAR-NK cells offer a promising immunotherapy approach, addressing key CAR-T cell limitations like reduced toxicity risks while retaining targeted efficacy. They combine the innate cytotoxicity of natural killer (NK) cells with the targeted action of chimeric antigen receptors (CAR). Their potential lies in efficacy, tolerability and the possibility of off-the-shelf production, enabling rapid treatment access. However, CAR-NK cells are still in early development with ongoing clinical trials. The next years will determine their potential for clinical application.